[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Adult patients with relapsed and refractory acute myelogenous leukemia usually demand further therapy aimed at achieving remission. The physician knows that life expectancy is limited. Care must be taken to choose a cytotoxic regimen where the potential gains outweigh the risks. Mitoxantrone and cytosine arabinoside were given in combination to 19 patients. Six achieved complete remission and increased survival. The side effects were acceptable.